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ABSTRACT: Virus-like particles are used to encapsulate
drugs, imaging agents, enzymes, and other biologically active
molecules in order to enhance their function. However, the
size of most virus-like particles is inﬂexible, precluding the
design of appropriately sized containers for diﬀerent
applications. Here, we describe a chromatographic selection
for virus-like particle assembly. Using this selection, we
identiﬁed a single amino acid substitution to the coat protein
of bacteriophage MS2 that mediates a uniform switch in
particle geometry from T = 3 to T = 1 icosahedral symmetry.
The resulting smaller particle retains the ability to be
disassembled and reassembled in vitro and to be chemically
modiﬁed to load cargo into its interior cavity. The pair of 27
and 17 nm MS2 particles will allow direct examination of the eﬀect of size on function in established applications of virus-like
particles, including drug delivery and imaging.
KEYWORDS: Protein engineering, protein supramolecular structure, virus structure, bacteriophage MS2, drug delivery, nanocontainers
Virus-like particles are attractive scaﬀolds for nanoengineer-ing. These particles are chemically and thermally stable,
easy to produce and assemble, and can be genetically modiﬁed
to encode changes to the protein nanostructure. Viral capsids
and virus-like particles have found applications as drug delivery
vehicles,1 imaging agents,2,3 nanobioreactors,4−6 light harvest-
ing arrays,7 and templates for inorganic synthesis.8,9 Many
strategies have been developed to decorate the interior and
exterior of such structures with useful chemical moieties10−12
and to encapsulate functional cargo in the cavity of these
structures.13−16 To date, a key limitation of virus-like particles
as drug delivery and imaging agents is the inability to tune
particle size to optimize serum half-life and tissue penetrance.17
We therefore set out to ﬁnd variants of the MS2 bacteriophage
coat protein that formed smaller virus-like particles, enabling
the comparison of protein containers of diﬀerent size but nearly
identical chemical composition.
MS2 bacteriophage virus-like particles have been investigated
for nanoscale patterning, drug delivery, and the study of
enzyme encapsulation. Each wild-type MS2 particle forms an
icosahedral capsid of approximately 27 nm in diameter.
Natively, each capsid consists of 178 copies of the coat protein
(CP) and one copy of the maturation protein (Mat, or A-
protein).18,19 Importantly, MS2 coat protein can be recombi-
nantly expressed and assembled in vitro to form an icosahedral
virus-like particle (VLP).14 These VLPs are of particular
interest in nanoengineering, in part due to their amenability to
chemical modiﬁcations and ability to disassemble and
reassemble in vitro around diverse forms of cargo.10−12,14 The
CP can also tolerate several amino acid mutations that render it
more amenable to targeted post-translational modiﬁcations for
various applications.12,20−22
In phage and VLPs, the MS2 CP forms dimers that assemble
into an icosahedron with 12 pentameric and 20 hexameric
facesa so-called T = 3 geometry. The structure of MS2
particles has been extensively characterized,23−26,14 but, as with
other multimeric assemblies, no point mutations are known to
confer uniform changes in the icosahedral supramolecular
structure adopted by the CP. If these could be identiﬁed, the
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mutants would serve as useful tools for exploring the eﬀects of
VLP size on engineered MS2 VLP performance for drug
delivery and imaging applications. Additionally, these unique
structural variants may also shed light on the structural
evolutionary landscape of the common T = 3 viral geometry.
Here we report that a single amino acid change to the MS2
CP confers a radical change in the MS2 VLP supramolecular
structure from a T = 3 icosahedron of 27 nm diameter to a T =
1 icosahedron of approximately 17 nm diameter consisting of
12 pentamers. This MS2 CP variant retains a similar dimer
conformation to the wild type, despite adopting a smaller
capsid structure. Moreover, it remains amenable to in vitro
reassembly, supports the incorporation of the Mat protein that
is required for infection, and tolerates a mutation that was
previously used to perform in vitro coupling of small molecules
to the interior of the MS2 VLP. Many applications of MS2
VLPs will therefore extend to this new structure, allowing a
side-by-side comparison of chemically similar VLPs of diﬀerent
sizes. These results also provide new insights into long-standing
debates on the evolution of viruses and gene-transfer agents as
well as the possibility for multiple stable forms of multiprotein
assemblies. Finally, we expect this work to inspire new
possibilities for the computational design of made-to-order
protein-based nanomaterials.
In order to identify mutants of the MS2 cp gene that encode
CP variants retaining the ability to assemble into VLPs, error-
prone PCR was used to generate a pool of mutated MS2 cp
genes (for details of this and other experimental procedures, see
the Methods section in the Supporting Information).
Approximately ﬁve nucleotide mutations were introduced in
each gene relative to the wild type, and the ﬁnal library size was
approximately 105 unique cp genes. The mutant genes were
expressed in E. coli (one copy per bacterial cell), and the
resulting naiv̈e pool was subjected to a chromatographic
selection for VLP assembly. The selection used was the same
procedure typically used to purify CPWT VLPs from E. coli.
Since each assembly competent VLP encapsulated the nucleic
acids encoding the peptides in its shell, deep sequencing of the
nucleic acids (DNA and RNA) from the naiv̈e library and
selected pool was used to reveal cp genes enriched by selection
for assembly. We focused on mutants identiﬁed after one round
of VLP packaging, that is, plasmid-based expression in E. coli
and puriﬁcation by precipitation followed by ion exchange and
size exclusion chromatography to isolate VLP-sized particles.
These VLPs were subjected to disruption and nucleic acid
isolation, followed by sequencing.27 We assessed enrichment at
each amino acid position by comparing the Shannon
information theoretic entropy at each position and discovered
that only residue Ser37 demonstrated an increase in Shannon
entropy upon selection (Supporting Information Figure S1).
Upon closer inspection, we were surprised to ﬁnd that 70.5% of
the reads in the pool selected for assembly encoded a Ser37Pro
mutation (as compared to 2.8% of reads in the naiv̈e library).
This mutation is observed in the literature only twice, arising
from selections in two separate directed evolution studies by
Peabody and colleagues, but it was not pursued further in either
study and was not characterized for size.28,29 Given that the
mutation arose only when selections did not include an
infection step, we speculated that perhaps this variation does
not yield infectious particles, precluding its observation in the
myriad other evolutionary studies of MS2 VLPs. We therefore
sought to examine the structural and biochemical properties of
this highly abundant CPS37P variant. The abundance of other
amino acid mutations in the selected pool is shown relative to
the naiv̈e library at each residue of the CP protein in Figure S2.
The mutant cp gene encoding the CPS37P mutant was
recapitulated and expressed in E. coli, and the resulting VLPs
exhibited similar properties to wild-type MS2 capsids
throughout puriﬁcation. Remarkably, transmission electron
microscopy (TEM) revealed that the particles formed of
CPS37P are smaller than the VLPs formed by the wild-type CP
(Figure 1A). This observation was conﬁrmed by dynamic light
scattering and size-exclusion chromatography (Figure S3). We
hypothesized that this smaller particle was likewise formed from
CP dimers but assembled into a diﬀerent geometry. We
therefore crystallized the CPS37P VLP and determined its
Figure 1. CPS37P dimers form a VLP of 17 nm diameter with a T = 1 icosahedral structure. (A) Transmission electron micrograph of CPS37P VLPs
and CPWT VLPs (inset). (B) Structural alignment of CPS37P (orange) and CPWT (blue) dimer structures. (C) Crystallographic asymmetric unit
structures (left) and complete VLP structures (right) from crystal structures of CPWT (top; 2MS2) and CPS37P (bottom; 4ZOR) VLPs. Hexameric
and pentameric capsomeres are outlined in red to highlight the T = 1 and T = 3 icosahedral geometries.
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structure by X-ray diﬀraction. The structures of the pentameric
asymmetric unit (ASU) and T = 1 icosahedral VLP of CPS37P
(PDB ID: 4ZOR) are shown alongside the structures of the
trimeric ASU and T = 3 icosahedral VLP of CPWT (PDB ID:
2MS2) (Figure 1C). Crystallographic statistics can be found in
Table S1, and a stereoscopic projection of a portion of electron
density map can be found in Figure S4. The ﬁve peptide chains
in the CPS37P ASU have nearly identical conformations but
diﬀer slightly in the “FG” loop, which surrounds the pore in the
center of the pentamer and lies in a region known to aﬀect
assembly.25,26 Interestingly, the proline residue at position 37
adopts a cis conformation in all ﬁve chains of the CPS37P ASU,
in contrast to the trans serine residue present at this position in
the CPWT VLP. This results in a slight but clear diﬀerence in
the conformation of a small loop directly adjacent to the S37P
mutation (Figure 1B). Notably, the interior volume of the
CPS37P VLP is much smaller than that of the wild-type particle,
and the CPS37P VLP encapsulates shorter genetic material than
the CPWT VLP when expressed recombinantly (Figure S5).
Since the CPS37P VLP is too small to permit encapsulation of
the full viral genome, we hypothesize that this mutation was not
observed previously because it cannot support infection30 of
E. coli.
The T = 1 geometry is favored in the case of CPS37P despite
surprisingly strong similarities between the CPWT and CPS37P
dimer structures. Investigation into the assembled structure
revealed that key structural changes occur at the dimer−dimer
interface. The interdimer angle between neighboring dimers
was smaller in the CPS37P VLP than in the CPWT VLP, as
expected given the formation of a smaller T = 1 icosahedral
supramolecular assembly. We speculated that this change in
interdimer interaction was due to diﬀerences in hydrogen
bonding. Indeed, several side chains near residue 37 are
positioned diﬀerently in the CPS37P structure as compared to
the CPWT structure, resulting in diﬀerent sets of hydrogen-
bonding interactions at the dimer−dimer interface. In
particular, the cis conﬁguration of Pro37 appears to change
the conformation of the side chain of Asn36 to interact with
Asn98, favoring a reconﬁguration of the hydrogen-bonding
interactions and changing the positioning and angle of the
dimer−dimer contact. Two hydrogen bonds were identiﬁed in
the CPS37P VLP near the Pro37 residue: the ﬁrst between the
carbonyl oxygen of Ile94 and the backbone nitrogen of Ser39
and the second between the side-chain oxygen of Asn98 and
the nitrogen of the Asn36 side chain (Figure 2). In the wild-
type structure, on the other hand, a hydrogen bond forms
between the backbone nitrogen of Asn98 and the side-chain
oxygen of Asn36.
To investigate the importance of these interdimer
interactions in the CPS37P VLP, we mutated the engineered
cp gene to disrupt the potential hydrogen bonds described
above, substituting an alanine at the Asn36 and Asn98 residues
to create the double mutants CPS37P/N36A and CPS37P/N98A and
the triple mutant CPS37P/N36A/N98A. The resulting variants
formed a mixed population of VLPs, comprising both 27 and
17 nm particles, as judged by TEM (Figure 2 and Figure S5).
Surprisingly, both the T = 3 and T = 1 icosahedral
conformations are apparently accessible to the CPS37P mutant
when either or both of these hydrogen bonds are disrupted.
However, the stability of these particles, as indicated by their
melting temperature, was less than that of both CPWT and
CPS37P VLPs (Table S2). We conclude that the hydrogen-bond
interaction between residues 36 and 98 stabilizes the T = 1
conﬁguration of CPS37P VLPs to a larger degree than the T = 3
conﬁguration of CPS37P VLPs. We also generated the analogous
single-point mutations in the wild-type cp gene, yielding CPN36A
and CPN98A proteins. The corresponding VLPs formed wild-
type size particles of 27 nm diameter, as determined by TEM
(Figure 2 and Figure S6), but also had lower melting
temperatures (Table S2). The assembly of these proteins into
VLPs of wild-type size indicates that the other interdimer
interactions that remain are suﬃcient to result in the formation
of wild-type-like VLPs. Moreover, it suggests that energetic
considerations beyond hydrogen bonding may be relevant to
VLP formation.
We next turned our attention to evaluating the utility of this
particle in established in vitro techniques designed for CPWT
VLPs. The CPWT VLP can be reassembled in vitro to
Figure 2. Hydrogen bonding contributes to the stability of T = 1 icosahedral CPS37P VLPs. (A) Structural alignment of CPS37P (orange) and CPWT
(blue) interdimer interface structures. Residues in (B) CPWT and (C) CPS37P structure altered to probe hydrogen-bonding interactions. Transmission
electron micrographs of VLPs formed of (D) CPN36A/S37P, (E) CPS37P/N98A, and (F) CPN36A/S37P/N98A. Blue arrows indicate VLPs of CPWT size (27
nm); orange arrows indicate VLPs of CPS37P size (17 nm).
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encapsulate RNA, DNA, negatively charged polymers, or
proteins bearing a negatively charged peptide tag. As such, it
is a useful biotechnological system for applications such as the
delivery of a nucleic acid, protein, or small-molecule payload to
cells by receptor-mediated endocytosis31,1,32 as well as
applications in nanoscale patterning and studies of enzyme
encapsulation. Indeed, we ﬁnd that VLPs composed of CPS37P
possess many of the same useful properties as VLPs formed of
wild-type CP. For example, CPN87C is a useful variant that
provides a cysteine residue in the VLP interior for modiﬁcation
via maleimide conjugation chemistry.20 We found that
CPS37P/N87C formed VLPs of 17 nm diameter amenable to
small molecule conjugation using Alexa Flour 488 maleimide,
similarly to wild-type CP VLPs (Figure 3). Moreover, VLPs
comprising the CPS37P variant could be disassembled and
reassembled around negatively charged cargo in vitro in similar
conditions to those identiﬁed for wild-type MS2 (Figure 4).14
Interestingly, when disassembled dimers from both CPWT and
CPS37P were combined at varying molar ratios, the resulting
population of VLPs comprised both 17 and 27 nm sized VLPs,
as determined by size exclusion chromatography and TEM. LC-
MS analysis of SEC fractions indicated that the smaller
population primarily consisted of CPS37P protein and the larger
population of CPWT, suggesting that the two variants
predominantly assemble separately.
We next evaluated whether the CPS37P mutation behaves
similarly to wild-type MS2 phage particle during the ﬁrst stage
of its infectious life cycle. Given the high mutation rate of
single-stranded RNA viruses, we expect that this single base pair
mutation occurs frequently in nature and that the resulting
particles might be capable of interacting with the E. coli host.
We therefore examined the ability of CPS37P VLPs to
incorporate the MS2 Mat protein, also known as the Assembly
(A) protein. The Mat protein is required for infection of F+
E. coli and is thought to interact with wild-type capsid C/C
dimer at the 2-fold axis.33 When the genes encoding both CPWT
and Mat are expressed simultaneously, approximately one Mat
protein is incorporated into each CPWT VLP.19 When we
isolated CPS37P VLPs produced in this manner and analyzed
their protein content by gel electrophoresis, a band was evident
at the expected molecular weight of the Mat protein, and its
identity was conﬁrmed as the Mat protein by mass
spectrometry (Table S3). Since the smaller particles are too
small to encapsulate an infectious MS2 genome, we applied
Figure 3. CPS37P/N87C VLPs are amenable to speciﬁc chemical conjugation with Alexa488 maleimide. Absorbance at 493 nm (A493; green traces) and
at 280 nm (A280; blue/orange traces) of eﬄuent from size exclusion chromatography of VLPs formed of CP
N87C (green dashed and blue traces) or
CPS37P/N87C (green solid and orange traces) without (A) or with (B) maleimide addition. (C) Mass spectrometry of SEC eﬄuent of VLPs formed of
CPWT CPN87C (blue traces) or CPS37P/CPS37P/N87C (orange traces) or and without maleimide addition. (D) Transmission electron micrograph of
VLPs formed of CPS37P/N87C.
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these VLPs to a culture of MS2-susceptible F+ E. coli and
observed attachment of CPS37P VLPs to the F-pilus, in lieu of a
plaque assay to identify infectious virions. We found that CPS37P
VLPs attached in a manner similar to that observed for the
CPWT VLP, as assessed by examination of the pili by TEM
(Figure 5 and Figure S7). This indicates that the CPS37P mutant
retains the ability to incorporate the maturation protein in the
virion and thus also the ability to interact with the E. coli surface
like an infectious particle.
The observation that a single amino acid change to the MS2
CP protein can mediate a stable switch in VLP structure from a
T = 3 to a T = 1 icosahedron has broad implications for
engineering VLP-based nanomaterials. While previous studies
demonstrated that altering assembly conditions and VLP cargo
can cause perturbations in the ﬁnal structure of a VLP,34−37 the
CPS37P mutant described here stably and uniformly adopts the
alternate T = 1 icosahedral structure in conditions identical to
those in which the native CP adopts a T = 3 icosahedral
structure. The close similarities in primary sequence and dimer
conformation of wild-type and CPS37P particles mean that the
two VLPs have nearly identical chemical properties, allowing
for well-controlled comparisons to be made between protein
containers of diﬀerent sizes (27 and 17 nm, respectively) in
engineering applications. The size of the encapsulating particle
is known to inﬂuence the performance of drug delivery
vehicles,17 and the size of the protein container may be similarly
Figure 4. CPS37P dimers reassemble in vitro to form VLPs. Transmission electron micrographs of VLPs reassembled in vitro from dimers of (A)
CPWT, (B) CPS37P, and (C) a 4:1 molar mixture of CPWT and CPS37P dimers. (D) Histogram of VLP size determined from transmission electron
micrograph of VLPs reassembled in vitro from a 1:1 molar mixture of CPWT and CPS37P dimers. (E) Absorbance at 280 nm (A280) of eﬄuent from
size exclusion chromatography of mixed, separately assembled VLPs (green), VLPs reassembled from mixed CPWT and CPS37P dimers (gray),
reassembled CPS37P VLPs (orange), and CPWT VLPs (blue). (F) Mass spectrometry of SEC eﬄuent fractions 1−5 from VLPs reassembled from
mixed CPWT and CPS37P dimers as indicated in the gray A280 trace in (E). CP
WT m/z is approximately 13 728; CPS37P m/z is approximately 13 738.
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important in the design of nanobioreactors to immobilize and
guide enzymatic pathways.
We expect our selection strategy, in which a diversiﬁed
library of coat protein gene mutants was subjected to a
chromatographic selection for assembly, to extend to other
virus-like particle systems. In principle, any virus-like particle
that encapsulates its corresponding genetic material could be
subjected to a selection for assembly (whether by chromatog-
raphy or otherwise), and assembly competent variants could
likewise be identiﬁed by deep sequencing of the selected pool.
Future investigations of the MS2 VLP may also reveal other
possible geometries, perhaps including the much larger T = 7
icosahedral geometry. Furthermore, future selections could
incorporate other selective pressures.
A deeper understanding of the sequence−structure relation-
ship is critical if we wish to fully realize the potential of
nanoscale, protein-based assemblies. Our work oﬀers an
excellent case study for researchers trying to identify the key
features important to multiprotein structure formation. It is
apparent that subtle changes in protein structure, and in
particular in intermolecular interactions, can manifest as
signiﬁcant changes in the higher-order structure adopted by a
multiprotein complex. Eﬀorts to computationally predict the
structure of multiprotein complexes and to design multiprotein
structures de novo are still underway, and the behavior we
observed in the case of the MS2 coat protein will be a valuable
test case for methods to predict the structures of multiprotein
assemblies. The change in interdimer angle seen in the CPS37P
T = 1 icosahedral assembly as compared to the wild-type VLP
occurs despite very little evident change in the conformation of
the dimers themselves. While hydrogen bonding seems to
contribute to the stability of the smaller T = 1 icosahedral
structure, other factors also contribute to the accessibility of the
T = 1 icosahedral structure to the CPS37P mutant. Together, our
experiments suggest that ﬁne-grained models of protein−
protein interactions will be required to fully describe the eﬀects
responsible for the T = 3 to T = 1 icosahedral transition we
observed. Simulating these interactions for large structures
made up of many protein subunits, such as viral capsids, is a
uniquely challenging problem, but with exciting possibilities if
successful. In particular, resulting advances in the prediction
algorithms could be applied to the design and engineering of
new VLP structures as well as to the study of virus evolution.
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